Table 3

Median and median percentage change from baseline to week 52 in serum lipid and inflammatory markers of cardiovascular disease in patients with RA

	GO-FORWARD: RA patients with an inadequate response to MTX				GO-BEFORE: MTX-naïve RA patients
	Golimumab+MTX				Golimumab+MTX
	Golimumab 100 mg + Placebo	50 mg	100 mg	Combined	Placebo+MTX	Golimumab 100 mg + Placebo	50 mg	100 mg	Combined
Patients randomised,† n	133	89	89	178	160	159	159	159	318
Serum lipid markers
Triglycerides (mg/dl)	−1.00	2.00	3.50	3.00	−4.00	2.00*	6.00	0.00	3.00*
Triglycerides (mg/dl)	−0.96%	1.81%	4.00%	3.37%*	−3.41%	2.41%*	8.01%**	0.00%	3.82%***
Total cholesterol (mg/dl)	8.00**	7.00**	11.50***	9.00***	5.00	3.00**	12.00**	8.00***	10.00***
Total cholesterol (mg/dl)	4.55%**	4.02%***	5.45%***	4.58%***	1.90%*	1.80%**	6.41%***	3.56%***	4.91%***
LDL (mg/dl)	8.50***	7.00***	11.50***	8.00***	6.00*	7.00**	8.00***	6.00***	7.00***
LDL (mg/dl)	8.48%***	6.19%***	9.50%***	7.09%***	6.08%**	5.93%**	7.80%***	6.04%***	6.56%***
HDL (mg/dl)	−1.00	0.00	1.50	0.00	−1.00	0.00	−0.50	0.00	0.00
HDL (mg/dl)	−2.49%	0.00%	1.78%	0.00%	−1.28%	0.00%	−0.85%	0.00%	0.00%
Total cholesterol/HDL	0.20***	0.10**	0.04	0.06***	0.12*	0.13**	0.23***	0.09*	0.14***
Total cholesterol/HDL	6.37%***	3.31%**	1.03%*	1.87%***	2.91%*	4.43%**	7.51%***	2.76%**	4.16%***
LDL/HDL	0.22***	0.09**	0.09*	0.09***	0.09*	0.12**	0.16***	0.15**	0.15***
LDL/HDL	9.46%***	5.09%***	4.65%**	5.03%***	4.52%**	5.25%**	8.64%***	7.98%***	8.19%***
Apolipoprotein B (mg/dl)	5.00**	2.00*	1.00	1.00*	0.00	3.00	3.00**	3.00*	3.00***
Apolipoprotein B (mg/dl)	5.43%***	2.35%**	1.57%	2.17%***	0.00%	3.33%	4.41%**	3.85%**	3.95%***
Apolipoprotein A1 (mg/dl)	5.00*	10.00***	12.00***	11.00***	6.00**	6.00**	7.00**	8.00***	8.00***
Apolipoprotein A1 (mg/dl)	3.16%**	6.88%***	8.30%***	7.51%***	4.55%***	4.55%**	5.08%***	5.59%***	5.26%***
Apolipoprotein B/	0.02	−0.02	−0.03*	−0.02***	−0.01	−0.01	0.00	0.00	0.00
Apolipoprotein A1 (mg/dl)	3.99%	−4.44%	−5.48%	−4.68%*	−3.14%	−1.82%	−1.10%	−0.69%	−0.69%
LDL subfractions
Total LDL particles (nmol/l)	66.50*	−28.00	−43.00	−31.00	−19.00	−49.00	−5.50	−3.50	−4.50
Total LDL particles (nmol/l)	4.92%*	−2.33%	−3.82%	−3.25%	−1.58%	−3.88%	−0.42%	−0.34%	−0.42%
Total small LDL (nmol/l)	−1.00	−98.00***	−105.00*	−105.00***	−53.00*	−104.00*	−28.50*	−72.50**	−46.50***
Total small LDL (nmol/l)	−0.39%	−17.87%**	−19.09%*	−18.93%***	−7.41%	−17.43%	−6.72%	−14.80%	−10.60%*
Very small LDL (nmol/l)	7.50	−78.00***	−85.00*	−78.00***	−37.00*	−76.00*	−19.00	−58.50*	−42.50***
Very small LDL (nmol/l)	0.62%	−19.17%**	−21.00%**	−19.81%***	−8.29%	−18.06%	−6.50%	−14.22%	−11.90%*
Medium small LDL (nmol/l)	2.50	−18.00***	−17.00*	−17.00***	−11.50*	−16.00*	−10.50*	−17.50*	−16.00***
Medium small LDL (nmol/l)	1.16%	−21.84%**	−19.51%*	−19.75%***	−9.30%	−13.26%	−14.68%	−17.11%	−15.38%*
Large LDL(nmol/l)	16.50	62.50***	71.00***	63.00***	38.50**	17.00	74.00***	54.00***	60.00***
Large LDL(nmol/l)	4.18%	12.28%***	14.12%***	13.30%***	14.56%**	4.28%	14.33%***	14.40%***	14.40%***
Mean LDL size (nM)	0.00	0.30***	0.20**	0.20***	0.20**	0.20	0.10**	0.20***	0.20***
Mean LDL size (nM)	0.00%	1.42%***	0.96%**	1.02%***	0.95%**	0.93%	0.48%**	0.93%***	0.91%***
Inflammatory markers
Serum amyloid A (µg/ml)	−1.70*	−8.80***	−5.60***	−8.00***	−21.30***	−7.30***	−15.80***	−11.90***	−12.50***
Serum amyloid A (µg/ml)	−32.14%*	−59.75%***	−57.76%***	−58.82%***	−76.57%***	−51.39%***	−72.58%***	−70.87%***	−72.50%***
hsCRP (mg/dl)	−0.64	−3.74***	−5.20***	−4.30***	−8.35***	−8.00***	−4.14***	−9.01***	−6.27***
hsCRP (mg/dl)	−18.60%	−56.73%***	−64.78%***	−56.93%***	−75.29%***	−61.54%***	−66.60%***	−71.73%***	−69.59%***
Fibrinogen (mg/dl)	−46.00*	−40.50***	−71.00***	−57.00***	−41.00**	−44.00**	−59.00***	−61.00***	−60.50***
Fibrinogen (mg/dl)	−11.75%	−10.73%***	−15.63%***	−12.00%***	−9.33%*	−11.55%*	−13.90%**	−12.00%***	−13.18%***
ICAM-1 (ng/ml)	−69.50***	−80.00***	−96.50***	−84.00***	−59.50***	−87.00***	−86.00***	−81.00***	−81.00^##/***
ICAM-1 (ng/ml)	−22.59%***	−25.00%***	−25.53%***	−25.17%***	−17.48%***	−26.32%***	−27.78%***	−24.23%***	−25.81%***
IL-6 (pg/ml)	0.95	−1.25**	−0.60**	−0.80***	−4.55***	−1.00*	−3.80***	−5.30***	−4.00^##/***
IL-6 (pg/ml)	16.92%***	−24.76%	−10.71%	−22.92%	−49.82%	−10.38%	−50.70%	−50.00%*	−50.35%*
IL-8 (pg/ml)	−1.60	−2.80***	−1.15**	−2.30***	−1.80	−0.20	−3.10***	−3.00***	−3.00***
IL-8 (pg/ml)	−9.61%	−16.21%	−10.74%	−13.30%*	−10.43%	−1.74%	−22.12%**	−18.63%**	−20.00%***
MMP-3 (ng/ml)	−10.54***	−15.73***	−16.82***	−16.20***	−24.43***	−13.53***	−25.76***	−18.71***	−22.21***
MMP-3 (ng/ml)	−32.72%***	−41.05%***	−44.74%***	−42.56%***	−56.46%***	−37.53%***	−61.74%***	−49.52%***	−57.34%***
VEGF (pg/ml)	−17.80***	−23.50***	−28.80***	−26.70***	−37.45***	−20.10***	−23.70***	−29.90***	−28.60***
VEGF (pg/ml)	−22.47%***	−27.60%***	−34.20%***	−31.78%***	−40.17%***	−25.74%***	−33.56%***	−35.11%***	−34.15%***

†Not all randomised patients had week 52 biomarker data.
*^, **^, ***indicate p<0.05, 0.01, 0.001, respectively, for change from baseline within group.
^{# #}indicates p<0.01, for the comparison of the combined golimumab+MTX and placebo+MTX groups.
HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; LDL, low-density lipoprotein; MMP-3, matrix metalloproteinase; MTX, methotrexate; RA, rheumatoid arthritis, VEGF, vascular endothelial growth factor.